Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.

Clinical pharmacokinetics - 1 Dec 2021

Kneller Lisa Alina, Zubiaur Pablo, Koller Dora, Abad-Santos Francisco, Hempel Georg

Abstract excerpt

BACKGROUND AND OBJECTIVES: Aripiprazole is an atypical antipsychotic drug that is metabolized by cytochrome P450 (CYP) 2D6 and CYP3A4, which mainly form its active metabolite dehydro-aripiprazole. Because of the genetic polymorphism of CYP2D6, plasma concentrations are highly variable between different phenotypes. In this study, phenotype-related physiologically based pharmacokinetic models were developed and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pain Management and Opioid Use

Share to Pharmacogenetics and Drug Metabolism

Share to Phenotype

Share to Piperazines

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 34125422
DOI: 10.1007/s40262-021-01041-x
PMCID: PMC8613074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.PMID 34125422Read ↗

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.Semantic proximity Read ↗

Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.Semantic proximity Read ↗

Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects.Semantic proximity Read ↗

Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.Semantic proximity Read ↗

Population pharmacokinetics of aripiprazole in healthy Korean subjects.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic ExposureSemantic proximity Read ↗

Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrationsSemantic proximity Read ↗

Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.Semantic proximity Read ↗

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.Semantic proximity Read ↗

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.